Patient descriptors
| UPN . | Sex . | Age at MM diagnosis . | MM therapy and time (PRE) . | All therapy (PRE) . | Interval between PRE sample and first ASCT (m) . | Second ASCT . | MM therapy (POST and preMN) . | From ASCT to MN (m) . | MN . | MN cytogenetics . | MN molecular . | Survival after MN diagnosis (m) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHM1 | M | 66 y 7mo | Dx | Len, Dex, XRT | 6 (sample NA) | N | Len | 84 | AEL/AML | 5q-, 7q-, 20q-; plasma cells with polysomy 14 | NA | 13 | CHF, AML progression |
| SHM2 | M | 64 y 4 mo | Dx | Cy, Bor, Len | 6 | N | Len, Dex | 19 | MDS | 44-46,XY,del(7)(q11.2),del(12)(p11.2),+13,add(14)(p11.2),-18, 44-46, XY, del7, del12, +13, add14, -18, −22, +mar[cp9]/46XY∗ | NA | 35 | Relapsed MM, sepsis |
| SHM3 | M | 56 y 1 mo | +3y | Bor Thal | 29 | N | None | 93 | AML | 42, XY 5(3;12), add4, del5q, −7, −15, −21, −22/43-46, idem, +1-4mar/46 XY | CEBPA/NPM1/FLT3/c-kit negative | 12 | AML relapse, pneumonia |
| SHM4 | M | 61 y 7 mo | Dx | Len, Dex | 7 | Y | Len | 106 | MDS | 44, XY, −4, −5, del7, add9, der12t(4;12), add18, add19/88, idemx2/46XY | CEBPA/NPM1/FLT3/c-kit negative | 21 | Relapsed MDS and MM, pneumonia |
| SHM5 | F | 62 y 4 mo | 2mo Len-Dex | Len | 7 | N | Len | 88 | AML | 42-43, X, r(x), dic(1;15), add4, -7, der8t(7;8), der11t(11;15), −15, −20, −22, +1-2mar | NA | 2 | Sepsis, AML progression |
| SHM6 | M | 69 y 6 mo | +4Mo | Len, Bor | 5 | N | Bor | 60 | AML | XY; PC: +1q, −13, −14q or −14 | NA | 27 | Persistent MDS |
| SHM7 | M | 71 y 0 mo | Dx- (seq fail) | Cy | 5 | N | Len | 105 | MDS | 46-39, XY, +1, −4, der(9)t(9;22), add12, der13, +add21 × 2, +1-2mar; tetrasomy 21; PC trisomy 1, deletion 4p or monosomy 4 | NA | 3 | MDS progression |
| SHM8 | M | 61 y 3 mo | +5mo 4 × Cy, Bor, Dex | Cy, Bor, Dex | 6 | N | Len, Bor, Dex | 19 | MDS | −5, −7 (per note) PC t11, likely hyperdiploidy | NA | 9 | MDS progression |
| UPN . | Sex . | Age at MM diagnosis . | MM therapy and time (PRE) . | All therapy (PRE) . | Interval between PRE sample and first ASCT (m) . | Second ASCT . | MM therapy (POST and preMN) . | From ASCT to MN (m) . | MN . | MN cytogenetics . | MN molecular . | Survival after MN diagnosis (m) . | Cause of death . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHM1 | M | 66 y 7mo | Dx | Len, Dex, XRT | 6 (sample NA) | N | Len | 84 | AEL/AML | 5q-, 7q-, 20q-; plasma cells with polysomy 14 | NA | 13 | CHF, AML progression |
| SHM2 | M | 64 y 4 mo | Dx | Cy, Bor, Len | 6 | N | Len, Dex | 19 | MDS | 44-46,XY,del(7)(q11.2),del(12)(p11.2),+13,add(14)(p11.2),-18, 44-46, XY, del7, del12, +13, add14, -18, −22, +mar[cp9]/46XY∗ | NA | 35 | Relapsed MM, sepsis |
| SHM3 | M | 56 y 1 mo | +3y | Bor Thal | 29 | N | None | 93 | AML | 42, XY 5(3;12), add4, del5q, −7, −15, −21, −22/43-46, idem, +1-4mar/46 XY | CEBPA/NPM1/FLT3/c-kit negative | 12 | AML relapse, pneumonia |
| SHM4 | M | 61 y 7 mo | Dx | Len, Dex | 7 | Y | Len | 106 | MDS | 44, XY, −4, −5, del7, add9, der12t(4;12), add18, add19/88, idemx2/46XY | CEBPA/NPM1/FLT3/c-kit negative | 21 | Relapsed MDS and MM, pneumonia |
| SHM5 | F | 62 y 4 mo | 2mo Len-Dex | Len | 7 | N | Len | 88 | AML | 42-43, X, r(x), dic(1;15), add4, -7, der8t(7;8), der11t(11;15), −15, −20, −22, +1-2mar | NA | 2 | Sepsis, AML progression |
| SHM6 | M | 69 y 6 mo | +4Mo | Len, Bor | 5 | N | Bor | 60 | AML | XY; PC: +1q, −13, −14q or −14 | NA | 27 | Persistent MDS |
| SHM7 | M | 71 y 0 mo | Dx- (seq fail) | Cy | 5 | N | Len | 105 | MDS | 46-39, XY, +1, −4, der(9)t(9;22), add12, der13, +add21 × 2, +1-2mar; tetrasomy 21; PC trisomy 1, deletion 4p or monosomy 4 | NA | 3 | MDS progression |
| SHM8 | M | 61 y 3 mo | +5mo 4 × Cy, Bor, Dex | Cy, Bor, Dex | 6 | N | Len, Bor, Dex | 19 | MDS | −5, −7 (per note) PC t11, likely hyperdiploidy | NA | 9 | MDS progression |
Pertinent clinical descriptors for the 8 patients in our study are detailed in this table.
AEL, acute erythroid leukemia; AML, acute myelogenous leukemia; Bor, bortezomib; CHF, congestive heart failure; Cy, cytoxan; Dex, dexamethasone; Dx, time of diagnosis with no prior therapy; IGH, immunoglobulin heavy locus; Len, lenalidomide; MDS, myelodysplastic syndrome; MN, myeloid neoplasm; N, no; NA, not available; PC, plasma cell; Thal, thalidomide; XRT, radiation therapy; Y, yes.1
MM cells with t11, +14q or IGH rearrangement, loss of 16q, TP53 deletion